Antitumor effect of Anlotinib hydrochloride on patients with advanced esophageal squamous cell carcinoma
Objective To observe the antitumor effect of Anlotinib hydrochloride on patients with advanced esophageal squamous cell carcinoma.Methods The clinical data of 36 patients with advanced esophageal squamous cell carcinoma treated with Anlotinib hydrochloride were retrospectively analyzed in our department from January 2020 to August 2023,and the clinical efficacy(CR,PR,PD,ORR,DCR)of the patients were recorded.The changes of serum tumor markers(CEA,CA125,SCC,cytokeratin 19 fragments)and inflammatory immune indicators(the white blood cells,neutrophils,CD4+T cells)were compared before treatment and after two cycles of treatment,and the adverse reactions of treatment were observed.Results 36 patients with advanced esophageal squamous cell carcinoma treated with Anlotinib hydrochloride,the ORR was 30.56％and DCR was 72.22％.Anlotinib hydrochloride can in-hibit the growth of esophageal cancer metastases.Serum tumor markers CEA,CA125 and SCC decreased after two cycles of treatment with Anlotinib hydrochloride compared with before treatment,and the difference was statistically significant(P＜0.05).There was no significant change in cytokeratin 19 fragments before treatment and after two treatment cycles,P=0.06.After two cycles of Anlotinib hydrochloride treatment,peripheral blood leukocytes and neutrophils decreased,P＜0.001.CD4+T cells increased after two treatment cycles with Anlotinib hydrochloride,P＜0.05.The adverse reactions we observed were mainly abdominal pain,diarrhea,fatigue,gin-giva pain,oral mucosal pain,hoarseness,and no serious adverse reactions were reported.Conclusion Anlotinib hydrochloride has antitumor effect in patients of advanced esophageal squamous cell carcinoma,and the adverse reactions are tolerable.
万方数据
维普
